A peptide blend fixes the ratio between its components at the moment of manufacture; a multi-vial stack leaves that ratio to the study design. Everything else — COA interpretation, concentration math, purity claims — follows from that one difference. Choosing peptide blends vs single vials is a study-design decision before it is a purchasing decision, and the most common error in the category is treating a co-formulated vial as if it were a single molecule. This guide sets out the three formats, the ratio and molarity arithmetic a blend forces on you, how a blend's certificate of analysis should differ from a single-peptide one, and when each format is the right tool. Research use only.
Peptide blends vs single vials: three formats, not two
| Format | What arrives | Ratio | COA expectation | Best for |
|---|---|---|---|---|
| Co-formulated blend | One vial, components lyophilized together | Fixed at manufacture | Per-component mass plus per-component purity | Fixed-ratio protocols, fewer handling steps |
| Multi-vial stack | Several sealed vials shipped as one item | Set by the researcher | One COA per vial, as for single peptides | Varying one component against a fixed background |
| Separate single vials | Individually ordered | Fully independent | One COA per lot | Any design where components vary independently or lots must be traced separately |
The Wolverine blend and the Wolverine Stack illustrate the distinction cleanly: the first is one vial of co-lyophilized BPC-157 and TB-500 at a fixed 1:1 mass ratio, the second is three separately sealed vials of BPC-157, TB-500 and GHK-Cu whose ratio is entirely yours to set.
Reading the ratio off a blend label
Blend labels state total mass and, when the ratio is not equal, the per-component split. A variant labelled 10 mg (5/5) contains 5 mg of each of two components. A variant labelled simply 80 mg, as on the four-component KLOW Blend, requires the COA to tell you how those 80 mg are divided — the split is not equal in most four-component preparations, and a blend whose documentation will not state per-component mass cannot be used quantitatively.
Worked example: concentration per component
- Start with the blend. A 10 mg (5/5) Wolverine vial reconstituted with 2 mL of diluent gives a total peptide concentration of 10 ÷ 2 = 5 mg/mL.
- Split it. Because the vial is 5 mg BPC-157 and 5 mg TB-500, the solution is 2.5 mg/mL of each, not 5 mg/mL of either.
- Per-unit mass. On a U-100 syringe, 0.01 mL (1 unit) contains 25 mcg of BPC-157 and 25 mcg of TB-500. A 0.1 mL draw is 250 mcg of each, 500 mcg total peptide.
- Compare with single vials. Achieving the same 2.5 mg/mL of each from separate vials means reconstituting a 5 mg BPC-157 vial with 2 mL and a 5 mg TB-500 vial with 2 mL — two reconstitutions, two septum entries per transfer, and the freedom to change either concentration later.
The underlying mg/mL arithmetic is the same one used for any vial and is covered in peptide reconstitution math explained.
The molarity trap: equal mass is not equal moles
This is the part that catches experienced researchers. A 1:1 mass ratio is not a 1:1 molar ratio unless the components happen to share a molecular weight, and they rarely do.
- BPC-157: 1,419.55 Da. At 2.5 mg/mL → 2.5 g/L ÷ 1,419.55 g/mol = 1.76 mM.
- TB-500: 889.02 Da. At 2.5 mg/mL → 2.5 ÷ 889.02 = 2.81 mM.
The same mass of each delivers roughly 1.6 times more molecules of TB-500 than of BPC-157. For a receptor-occupancy or stoichiometry question, that is the number that matters, and a fixed-mass blend cannot be adjusted to correct it. Any design that needs equimolar components needs single vials.
What a blend COA should show
A single-peptide certificate reports one HPLC purity figure and one mass-spectrometry identity confirmation. A blend cannot be summarised that way, and the honest documentation looks different:
- Per-component purity, measured before blending. Each peptide should be synthesised, purified and released against its own COA, then combined. "≥99% purity" on a blend normally means each input met that specification, not that the mixture has a single 99% peak.
- A chromatogram that resolves the components. On a reversed-phase run, four peptides of different hydrophobicity elute at four different retention times. A blend chromatogram should show the expected number of peaks with the expected area ratios; a single broad peak is a red flag.
- Per-component mass in the vial, established gravimetrically at fill or by quantitative amino-acid analysis.
- An identity confirmation per component. A blend has several molecular weights, and MS should account for all of them.
The general framework for reading these documents is in how to read a peptide COA. If a supplier's blend COA reports a single purity number and a single mass with no per-component breakdown, the document does not describe the product.
When each format is the right choice
Choose a co-formulated blend when
- The protocol specifies a fixed ratio you do not intend to vary — the case for CJC-1295 + Ipamorelin, where the two secretagogues act on different receptors converging on the same cell and the pairing is the established research configuration.
- Handling steps are a meaningful source of error. Every reconstitution adds pipetting variance, a septum puncture and a contamination opportunity; a four-component blend removes three of each.
- Total material cost per milligram matters and the ratio is acceptable as supplied.
Choose separate vials or a stack when
- One component is being varied against the others — the defining requirement of a concentration–response design.
- Equimolar rather than equal-mass comparison is required.
- Components have materially different stability. Copper peptides, methionine-containing sequences and disulfide-bonded peptides degrade on different timelines; once co-formulated in solution, the whole vial is limited by its least stable member.
- Lot traceability per component is required for publication or for internal QC.
- Components need different diluents or different pH ranges to dissolve cleanly.
The NAD+ Longevity Stack is the archetype of the second column: three individually sealed vials priced as a kit, reconstituted independently.
Common mistakes
- Treating total vial mass as per-component mass. An 80 mg four-component vial does not contain 80 mg of anything.
- Assuming an equal mass split when the label does not state one.
- Reporting molar concentrations for a blend without recalculating each component against its own molecular weight.
- Accepting a single purity figure for a multi-component vial.
- Splitting a blend to recover one component. Once co-lyophilized, the components cannot be separated without preparative chromatography; if you need one peptide alone, buy it alone from the lyophilized vial range.
The full co-formulated and multi-vial range sits in peptide blends and stacks.